LBRX - NASDAQ

LB Pharmaceuticals Inc Common Stock

LBRX·NASDAQ

$27.95

+3.4%

HealthcareBiotechnology

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$801.51M

EPS-1.0000

P/E Ratio-27.95

Earnings Date06/25/2026

lbrx

Other Current Liabilities

Last Annual Value

2.90M

3-Year CAGR

136%

5-Year CAGR

67%

10-Year CAGR

29%

Adjust for Inflation

LB Pharmaceuticals Inc Common Stock Competitors Analysis of Other Current Liabilities

LBRX · NASDAQ

Company	Other Current Liabilities	CAGR 3Y	CAGR 5Y	CAGR 10Y
LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX	2.90M	53.8%	N/A	N/A
Aura Biosciences, Inc. NASDAQ:AURA	13.59M	144.1%	38.6%	N/A
Annexon, Inc. NASDAQ:ANNX	24.79M	63.7%	64.5%	N/A
Editas Medicine, Inc. NASDAQ:EDIT	-11.90M	N/A	N/A	N/A
Humacyte, Inc. NASDAQ:HUMA	10.54M	25.8%	20.7%	N/A
Kyverna Therapeutics, Inc. NASDAQ:KYTX	27.21M	40.7%	73.8%	N/A
Lyell Immunopharma, Inc. NASDAQ:LYEL	46.52M	74.2%	10.5%	N/A
Replimune Group, Inc. NASDAQ:REPL	6.07M	-22.2%	6.3%	N/A
Tenaya Therapeutics, Inc. NASDAQ:TNYA	8.56M	-2.6%	9.7%	N/A
Rocket Pharmaceuticals, Inc. NASDAQ:RCKT	27.29M	40.1%	43.2%	24.8%
Korro Bio, Inc. NASDAQ:KRRO	-221.00K	N/A	N/A	N/A

LB Pharmaceuticals Inc Common Stock Fair Value Envelope

LBRX · NASDAQ

Our analysis suggests that LBRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.95, this represents a potential HIDDEN relative to our calculated worth for LB Pharmaceuticals Inc Common Stock.

HIDDEN

Intrinsic Value

Current Price: $27.95

Related Guides

Blog Categories

Continue your LBRX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.